Noramco Invests $25M in Halo Pharma’s Whippany Facility for Sterile Injectable Manufacturing The Noramco Group, a North American provider of integrated API and drug product supply chain services, has announced…
NeoGenomics Acquires Pathline to Expand Oncology Testing in the Northeast NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing services, has announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified…
Study Confirms HER2DX® Assay’s Impact on Early-Stage HER2-Positive Breast Cancer Decisions REVEAL GENOMICS®, an innovative biotech company based in Barcelona, is excited to announce the publication of a groundbreaking study…
IMFINZI® Regimen Shows Improved Survival in Early-Stage Gastric and GEJ Cancers AstraZeneca’s innovative perioperative treatment combining IMFINZI® (durvalumab) with standard chemotherapy has shown significant improvements in survival outcomes for patients…
Scribe Therapeutics Presents Epigenetic X-Repressor Data at 2025 Keystone Symposium Scribe Therapeutics Inc. (Scribe), a leading genetic medicines company leveraging the power of CRISPR technology to transform human health, recently…
Sensorion Completes Patient Enrollment in NOTOXIS Phase 2a Trial of SENS-401 Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on developing novel therapies for hearing loss, has announced the…
Sensus Healthcare to Showcase Products at AAD Annual Meeting Sensus Healthcare, Inc. (Nasdaq: SRTS), a leader in non-invasive and cost-effective treatments for skin conditions, will showcase its complete line of…
bioAffinity Technologies Plans $4 Million Cost Cut to Boost CyPath® Lung Sales bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive testing for early-stage lung cancer and…
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy: Access, Regulations, and Trials Italfarmaco S.p.A. has announced significant progress in the regulatory and clinical development of givinostat, its investigational drug for…
ENCell’s EN001 Gets FDA Orphan Drug Status for Charcot-Marie-Tooth Disease ENCell, a leading biopharmaceutical company specializing in cell and gene therapy, contract research, and manufacturing, has announced that the U.S.…
Elegen Reduces Pricing for ENFINIA™ DNA to Expand Access to Next-Generation Cell-Free DNA Manufacturing Elegen, a pioneer in next-generation cell-free DNA manufacturing, has announced a 25% price reduction for its…
FDA Accepts Gazyva sBLA for Lupus Nephritis Treatment Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License…